drugset / Trial / NCT02249221

Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

NCT02249221

Phase 1/2 Completed 84 enrolled Green Cross Corporation
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of GC3106 after single intramuscular administration in Korean healthy adults.

Timeline

Start
2014-10
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject GC3106 Vaccine 0.5 ml Intramuscular
Comparator Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular

Indications